Table 1.
Participant Characteristics (n = 275)
| Participant Characteristics | Value |
|---|---|
| Age (years); mean (SD) | 54.1 (11.2) |
| Gender; n (%) | |
| Female | 84 (30.5) |
| Male | 191 (69.5) |
| Clinical AJCC staging; n (%) | |
| I | 23 (08.4) |
| II | 81 (29.5) |
| III | 92 (33.4) |
| IVa | 76 (27.6) |
| IVb | 3 (01.1) |
| Tumor status; n (%) | |
| T1 | 135 (49.1) |
| T2 | 45 (16.4) |
| T3 | 57 (20.7) |
| T4 | 38 (13.8) |
| Nodal status; n (%) | |
| N0 | 38 (13.8) |
| N1 | 105 (38.2) |
| N2 | 87 (31.6) |
| N3 | 45 (16.4) |
| Metastatic status; n (%) | |
| M0 | 272 (98.9) |
| M1 | 3 (01.1) |
| Treatment regimen; n (%) | |
| RT alone | 15 (05.5) |
| Chemoradiotherapy | 260 (94.5) |
| Recurrence; n (%) | |
| No | 257 (93.5) |
| Yes | 18 (06.5) |
| Questionnaire | |
| SNOT-22 score; mean (SD) | 24.1 (19.9) |
| ETDQ-7 score; mean (SD) | 16.7 (09.8) |
| Acquiring time after RT (months); median (IQR) | 50 (29, 93) |
Abbreviations: AJCC, American Joint Committee on Cancer; ETDQ, eustachian tube dysfunction questionnaire; IQR, interquartile range; RT, radiotherapy; SD, standard deviation; SNOT-22, 22-item Sino- Nasal Outcome Test.